Diskusjon Triggere Porteføljer Aksjonærlister

Hofseth Biocare (HBC.OL)

Starter en tråd om HOFSETH BIOCARE AS (HBC.OL) siden en del har den i favoritt-listen eller i porteføljen sin :slight_smile:

Hofseth BioCare ASA, a biotech company, develops, manufactures, markets, and sells marine ingredients and finished products for humans and pets in Norway. Its products include OmeGo salmon oil; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; and CalGo, a marine calcium powder produced from salmon bones that enhances bone density and bone deposition in older individuals.

The company was founded in 2000 and is headquartered in Ålesund, Norway.

La oss starte diskusjonen! @Leolion @Biotec @Thefunkybunch @ackb @pdx

Denne kan stenges, finnes tråd fra før. :slight_smile:

1 Like

Hofseth Biocare ASA: Preclinical research with OmeGo® demonstrates potential to treat eosinophilic asthma

Hofseth Biocare ASA: First Quarter 2020 Financial Report

Hofseth Biocare ASA:

Hofseth Biocare ASA: Completed Annual General Meeting

Hofseth Biocare ASA: HBC has begun protocol development for its accelerated Phase 2 clinical trial with OmeGo® to decrease Acute Respiratory Distress Syndrome and the need for assisted respiration in COVID-19 patients

Hofseth Biocare ASA: SHARE CAPITAL DECREASE REGISTERED - NEW PAR VALUE

Nytt pålydende 13.08.2020

New face value 13.08.2020

Hofseth Biocare ASA: CORRECTION: SHARE CAPITAL DECREASE REGISTERED - NEW PAR VALUE

Hofseth Biocare ASA: STRENGTHENS R&D FUNCTION WITH THE HIRING OF DR. ERLAND HERMANSEN AS MEDICAL DIRECTOR FOR CLINICAL DEVELOPMENT

Hofseth Biocare ASA: HBC AQUIRES A 34 PERCENT STAKE IN HEALTHCARE AND PETCARE DISTRIBUTOR ATLANTIC DELIGHTS LTD FOR ACCESS TO CHINESE MARKET

Hofseth Biocare ASA: SECURES DISTRIBUTION WITH A GLOBAL RETAILER GIANT IN THE UK, SPAIN, ICELAND, AND ONLINE FOR BRILLIANT SALMON OILT FOR PETS

Hofseth Biocare ASA: ISSUANCE OF NEW SHARES FOLLOWING EXERCISE OF OPTIONS - PRIMARY INSIDER DISCLOSURE

Hofseth Biocare ASA: SECOND QUARTER & HALF YEAR 2020 FINANCIAL REPORT

Hofseth Biocare ASA: New study highlights the potential of OmeGo® as a prophylactic therapy for Asthma and COPD

Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED

Hofseth Biocare ASA: ANNOUNCES THE USE OF A VIRTUAL PLATFORM TO RECRUIT COVID-19 PATIENTS IN CANADA TO THE PHASE 2 TRIAL. WILL ALSO ASSESS THE IMPACT OF OMEGO ON HOSPITALISED PATIENTS WITH SEVERE FORMS OF COVID-19 IN MEXICO AND BRAZIL